Codon, Blue Heron Settle Gene-Sythesis Patent Suit
The financial terms of the settlement deal were not disclosed, but Blue Heron will get a perpetual, fully paid sublicense to keep using error-correction technology in its commercial gene-synthesis activities and a release concerning its past activity.
Codon will ask the U.S. District Court for the District of Delaware to dismiss its complaint with prejudice.
Codon President Brian M. Baynes...
To view the full article, register now.